Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q96E35
UPID:
ZMY19_HUMAN
Alternative names:
Melanin-concentrating hormone receptor 1-interacting zinc finger protein
Alternative UPACC:
Q96E35; Q5T366
Background:
Zinc finger MYND domain-containing protein 19, also known as Melanin-concentrating hormone receptor 1-interacting zinc finger protein, plays a crucial role in the regulatory mechanisms of GPR24/MCH-R1 signaling. This protein's involvement in signaling pathways highlights its importance in cellular communication and physiological processes.
Therapeutic significance:
Understanding the role of Zinc finger MYND domain-containing protein 19 could open doors to potential therapeutic strategies. Its pivotal role in signaling pathways suggests its potential as a target for drug discovery, aiming to modulate its activity for therapeutic benefits.